Event Date/Time: Sep 27, 2008 End Date/Time: Sep 30, 2008
Registration Date: Jul 31, 2008
Abstract Submission Date: Jul 31, 2008
Report as Spam

Description

Viral Vector Vaccines
Date: 28th - 30th Sep 2008

Location/Venue: Wellcome Trust Conference Centre
Wellcome Trust Genome Campus
Hinxton
Cambridgeshire
CB10 1RQ

Information:


Viral vector vaccines represent the most rapidly growing area of vaccine development. Most of the leading vaccines in clinical development for the major infectious diseases, HIV, tuberculosis and malaria are viral vectors. For example, only two tuberculosis vaccines are reportedly in trials in the developing world, one an MVA vector and the other an adenoviral vector. Leading HIV programmes from Merck and NIH have been developing adenoviral vectors, and major European programmes include MVA vectors. Likewise, two of the leading malaria vaccine programmes are based on viral vectors.

In the cancer field at least two viral vector products are in phase III licensure trials for renal cancer and cervical neoplasia, and these are supported by major companies.

Viral vector vaccines for companion animals, mainly avipox vectors, are already on the market, and a candidate vaccine for foot and mouth disease control in cattle and pigs is an adenovirus vector. For avian influenza a fowlpox recombinant is widely used in Asia to prevent H5N1 in chickens and a MVA-based influenza vaccine aiming at cross-strain protection in humans and fowl is entering clinical trials.

Finally, numerous therapeutic vaccines for the immunotherapy of viral infections such as HIV, HBV and HCV are in clinical trials, with some initial evidence of efficacy.

However, these four fields have been developing with little contact. This meeting will encompass all four and address common challenges in taking this technology to licensure. These include manufacturing challenges, especially to ensure low cost supply for developing world and livestock markets, safety issues relating to the use of live viruses at large scale, and also environmental issues related to their release. Safety issues have been highlighted recently with the stopping of a phase IIb efficacy trial of Merck’s HIV adenovirus vaccine. Also, recent advances in immunomonitoring, especially the advent of sensitive polychromatic flow cytometry techniques, promise to advance efforts to define immune correlates of protection.

This meeting, bringing together all these fields to discuss progress, review safety issues and identify common priorities for accelerated development, should be both unique and timely.



Scientific Programme Committee:



Martin Friede - World Health Organisation

Adrian Hill - The Jenner Institute

Gary Nabel - National Institutes of Health



Sessions:



Immunobiology of Viral Vectors

Immunology and Viral Diseases

Cancer

Safety and Regulatory Aspects

TB and Malaria

Barriers to the Development of Vectored Vaccines





Speakers include:



David Baltimore - California Institute of Technology

Glyn Hewinson - Veterinary Laboratories Agency

Helen McShane - Jenner Institute

Andreas Neubert - IDT Biologika

Alfredo Nicosia - Okairos

Tom Richie - Naval Medical Research Center

Harriet Robinson - GeoVax Inc.

Jerald Sadoff - Aeras Global TB Vaccine Foundation

John Shiver - Merck Research Laboratories

Jim Tartaglia - SanofiPasteur

Jim Wilson - University of Pennsylvania





A conference programme will be confirmed shortly



Registration Fees:

Student No Accommodation £150
Student Twin Accommodation £235
Student Single Accommodation £285
Academic No Accommodation £250
Academic Twin Accommodation £335
Academic Single Accommodation £385
Commercial No Accommodation £350
Commercial Twin Accommodation £435
Commercial Single Accommodation £485


Registration & Abstract Deadline is 31st July 2008
Payment will be requested in full, after the registration deadline.
To register click here


The housing packages include registration, food and accommodation for the nights of the 28th and 29th September 2008. If you require additional nights this will be at an additional cost, please contact us directly for availability. The no housing package includes all costs accept accommodation. As we have limited bedrooms on-site this will be on a first come first serve basis, then delegates will be required to source their own accommodation. A daily shuttle service will be provided for those staying in Cambridge.

The meeting will include a poster session. We request that registrants abstract must be no more than 250 words and include a title, author name (s), institutions (s) and country of origin. Abstract submission and registration deadline is Thursday 31st July 2008. Please email your abstract to
l.hubbard@wtconference.org.uk.

After the registration and abstract deadline the scientific committee will assess your abstract and you will be notified whether you have been selected for a poster presentation. Registration fees will then be requested.

On Sunday 28th September, the meeting will open with registration at 13:30. The first session will commence at 15:00. The meeting will close late afternoon on Tuesday 30th September.

Venue

Wellcome Trust Genome Campus
Hinxton
Cambridge
United Kingdom
MORE INFO ON THIS VENUE